Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
weaker decrease » greater decrease (Expand Search), water decreases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
weaker decrease » greater decrease (Expand Search), water decreases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
-
1261
-
1262
-
1263
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1264
-
1265
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1266
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1267
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1268
-
1269
-
1270
-
1271
-
1272
-
1273
-
1274
-
1275
-
1276
-
1277
-
1278
-
1279
-
1280